Does Blue Shield of California Cover Prolia?

What Is Prolia and Why Is It Prescribed?

Prolia is the brand name for denosumab 60 mg, a fully human monoclonal antibody that inhibits RANK ligand (RANKL), the key cytokine that drives osteoclast-mediated bone resorption. The FDA approved Prolia in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and the label has since expanded to include men with osteoporosis, glucocorticoid-induced osteoporosis, and bone loss associated with hormone-ablation therapy in prostate and breast cancer patients. FDA approval record.

How Prolia Works in Bone

By binding RANKL, Prolia prevents osteoclast formation, function, and survival. The result is a measurable reduction in bone resorption markers within days and a sustained increase in bone-mineral density (BMD) over 36 months. In the key FREEDOM trial (N=7,808), Prolia reduced the risk of new vertebral fractures by 68% at 36 months compared with placebo (P<0.0001) and cut hip fracture risk by 40% (P=0.04) [1].

FDA-Approved Indications That Blue Shield Recognizes

Blue Shield's medical-necessity criteria track the FDA label closely. Coverage is typically available for:

• Postmenopausal osteoporosis in women at high fracture risk (T-score <-2.5 or prior fragility fracture)
• Osteoporosis in men at high fracture risk on androgen-deprivation therapy for prostate cancer
• Glucocorticoid-induced osteoporosis in patients taking ≥7.5 mg prednisone equivalent daily for ≥6 months
• Bone loss from aromatase inhibitor therapy in women with breast cancer

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines classify Prolia as a first-line agent for postmenopausal osteoporosis in patients with a T-score <-2.5 who cannot tolerate or have failed oral bisphosphonates [2].

Does Blue Shield of California Actually Cover Prolia?

Yes. Blue Shield of California lists denosumab (Prolia) on its formulary for commercial, Covered California, and Medicare Advantage plans, but coverage is conditional on prior authorization approval. Without that approval, members pay the full average wholesale price, which runs approximately $1,350 per injection [3].

Commercial Plan Coverage

On Blue Shield's commercial PPO and HMO formularies, Prolia typically sits on Tier 4 or Tier 5 (specialty biologic). After a deductible is met, member cost-sharing is commonly 20%, 30% coinsurance or a fixed specialty copay of $100, $300 per dose, depending on the specific plan design. Members enrolled in a High-Deductible Health Plan (HDHP) may owe the full negotiated rate until the deductible is satisfied.

Covered California (ACA Exchange) Plans

Exchange plans sold by Blue Shield follow the same formulary structure but must comply with California's drug cost-sharing rules under SB 17 and the ACA's out-of-pocket maximum provisions. For 2025, the ACA out-of-pocket maximum for individual coverage is $9,450, so even members on high-cost specialty tiers have a ceiling on total annual exposure.

Medicare Advantage (Blue Shield Promise Health Plan)

Under Blue Shield's Medicare Advantage products, Prolia is covered as a Part D specialty drug when administered at home or as a Part B benefit when administered in a physician's office. Part B billing (HCPCS code J0897) often results in lower member cost-sharing (20% of the Medicare-allowed amount after the Part B deductible of $240 in 2025) compared with Part D specialty tier cost-sharing. Confirming which pathway your provider will use before the injection is injected is worth the five-minute phone call.

Prior Authorization Requirements for Prolia

Prior authorization (PA) is required on nearly all Blue Shield plans. The PA process exists because Prolia costs roughly 10 to 20 times more per year than generic alendronate, the first-line bisphosphonate recommended in AACE and NOF guidelines [2][4].

What Documentation Blue Shield Typically Requires

Blue Shield's PA criteria for Prolia generally require the prescribing provider to submit:

1. A DXA (dual-energy X-ray absorptiometry) scan report showing a T-score <-2.5 at the spine or hip, or documentation of a prior fragility fracture
2. A clinical diagnosis of osteoporosis (ICD-10: M81.0, M80.00x, or applicable variant)
3. Documentation of at least one bisphosphonate trial lasting ≥12 months, OR a documented clinical reason why bisphosphonates are contraindicated or not tolerated (e.g., severe esophageal disease, creatinine clearance <35 mL/min, or a prior atypical femoral fracture on bisphosphonate therapy)
4. Prescriber's attestation that the patient is not currently pregnant and has adequate dental evaluation completed (given the risk of osteonecrosis of the jaw)
5. Confirmation that serum calcium and vitamin D levels have been checked and repleted if deficient, per FREEDOM trial safety protocol [1]

The PA approval period is typically 12 months (covering two injections), after which reauthorization is required.

Step Therapy: The Bisphosphonate-First Requirement

Most Blue Shield commercial plans apply a step therapy protocol requiring documented trial and failure of at least one generic bisphosphonate before Prolia is approved. Alendronate 70 mg once weekly is the most commonly required agent, given its 2003 FDA approval, low generic cost (under $10/month at most pharmacies), and efficacy data showing a 47% reduction in hip fracture risk in the FIT trial (N=2,027) [5].

Step therapy can be waived when a prescriber documents one of the following:

• GI contraindication (Barrett's esophagus, active esophagitis, inability to remain upright 30 minutes post-dose)
• Renal impairment (creatinine clearance <35 mL/min, per the Prolia prescribing information)
• Prior atypical femoral fracture on bisphosphonate therapy
• Documented allergy or serious adverse reaction to all available bisphosphonates

California law (Health and Safety Code Section 1367.206) requires that step therapy exceptions be processed within 72 hours for urgent cases and 3 business days for standard requests. Physicians should document the contraindication explicitly in the PA request letter, not just in the chart.

How to Get Prolia Approved by Blue Shield

A structured approach can cut the PA turnaround time significantly. The steps below reflect current Blue Shield PA pathways as of early 2025.

Step 1: Confirm the DXA Is on File

A DXA result must be no older than 24 months for Blue Shield to consider it current. If the patient's last DXA is older, order a new scan before submitting the PA. The WHO fracture-risk diagnostic thresholds (T-score <-2.5 = osteoporosis; T-score -1.0 to -2.5 = osteopenia) apply [6].

Step 2: Pull the Correct PA Form

Blue Shield uses CoverMyMeds or its own online portal for specialty drug PAs. Search for "denosumab" or "Prolia" specifically. The oncology indications (bone metastasis) use a separate form from the osteoporosis indications.

Step 3: Attach Bisphosphonate Trial Records or Contraindication Letter

A pharmacy dispensing record or a clinical note documenting the drug name, dose, duration, and reason for discontinuation satisfies step therapy documentation requirements. A single paragraph on practice letterhead, signed by the treating physician, also satisfies the requirement when a contraindication exists.

Step 4: Follow Up at 48 Hours

Blue Shield's standard PA review window is 3 to 5 business days for non-urgent requests. Calling the provider services line at 48 hours to confirm receipt of the PA package prevents the 7-to-10-day delays that occur when faxes are lost or documents are missing.

Step 5: Schedule the Injection Immediately After Approval

Prolia is given every 6 months (180 days, plus or minus 30 days). Missing the injection window by more than 7 weeks is associated with a measurable rebound increase in bone resorption markers and a reported increase in vertebral fracture risk [7]. Once the PA is approved, scheduling the first injection within 2 weeks protects the patient clinically and prevents a lapse that could trigger re-authorization.

What Happens If Blue Shield Denies Prolia?

Denial does not mean the patient cannot get Prolia. Three formal options exist.

Peer-to-Peer Review

Within 3 business days of a denial, the prescribing physician can request a peer-to-peer call with the Blue Shield medical director reviewing the case. Peer-to-peer review overturns 30%, 50% of specialty drug denials in published plan data [8]. The prescriber should have the DXA report, the bisphosphonate trial documentation, and the FRAX score (10-year fracture probability) ready for the call. A FRAX hip fracture probability ≥3% or major osteoporotic fracture probability ≥20% meets the National Osteoporosis Foundation's intervention threshold and strengthens the clinical argument [4].

First-Level Internal Appeal

If peer-to-peer fails, a written first-level appeal must be filed within 180 days of the denial notice under California Department of Managed Health Care (DMHC) rules. The appeal should include a letter from the prescriber, the FREEDOM trial data showing 68% vertebral fracture risk reduction [1], and any applicable AACE or NOF guideline language recommending Prolia as first-line in high-risk patients. AACE states: "Denosumab is recommended as first-line therapy for patients with osteoporosis who have a high fracture risk, particularly those who cannot take or have failed oral bisphosphonates" [2].

Independent Medical Review (IMR)

California's DMHC Independent Medical Review program allows members to request an external, binding review of any coverage denial involving medical necessity. IMR is free to the member. The DMHC overturned approximately 27% of IMR requests in the 2023 annual report, with musculoskeletal cases among the most frequently overturned categories [9]. Filing an IMR simultaneously with the internal appeal is allowed and often accelerates resolution.

Cost and Patient Assistance Programs

Even after approval, cost-sharing can be a barrier. Several programs can reduce the member's net cost to near zero.

Amgen SupportPlus

Amgen, Prolia's manufacturer, operates the SupportPlus program, which provides Prolia at no cost to commercially insured patients who meet income and eligibility criteria. The program also offers a co-pay card that can reduce commercial plan cost-sharing to $0 per dose for eligible patients. Providers and patients can enroll at amgensupportplus.com or by calling 1-888-772-6436.

State Pharmaceutical Assistance

California's Medi-Cal program covers Prolia for eligible low-income patients under the Medi-Cal formulary with PA requirements similar to Blue Shield's. Dual-eligible patients (Medicare and Medi-Cal) may have cost-sharing reduced to $0 through the Low-Income Subsidy (LIS) program administered by CMS [10].

340B Program

Patients receiving care at a federally qualified health center or other 340B-covered entity may access Prolia at the 340B ceiling price, which is substantially below the commercial rate. Providers at 340B facilities should verify eligibility through the HRSA database [11].

Clinical Context: Why Prolia Is Often Worth Fighting For

The clinical stakes around osteoporosis treatment are significant. The National Osteoporosis Foundation estimates that 10.2 million Americans have osteoporosis and another 43.4 million have low bone mass [4]. A single hip fracture carries a 1-year mortality rate of approximately 21%, 23% in adults over 65, and 50% of patients who survive a hip fracture never fully regain their prior level of function [12].

FREEDOM Trial: The Evidence Behind Prolia's Coverage Fight

The FREEDOM trial enrolled 7,808 postmenopausal women aged 60 to 90 with a lumbar spine or total hip T-score between -2.5 and -4.0. At 36 months, denosumab 60 mg every 6 months produced [1]:

• 68% reduction in new vertebral fracture risk (7.2% placebo vs. 2.3% denosumab; P<0.001)
• 40% reduction in hip fracture risk (1.2% placebo vs. 0.7% denosumab; P=0.04)
• 20% reduction in non-vertebral fracture risk (8.0% placebo vs. 6.5% denosumab; P=0.01)

These numbers give prescribers strong evidence to present during peer-to-peer review or appeals.

Rebound Risk: Why Continuity of Coverage Matters

Discontinuing Prolia without transitioning to a bisphosphonate leads to a rapid rise in bone turnover markers and an increased risk of multiple vertebral fractures within 12 to 18 months of the last dose [7]. A 2017 case series and subsequent analyses reported vertebral fracture rates as high as 7% per patient in the year after Prolia discontinuation without bridging therapy [13]. This safety concern gives prescribers a medically compelling reason to argue against coverage lapses and for smooth renewal of PA approvals. The Endocrine Society recommends a single dose of zoledronic acid or a 1-to-2-year course of alendronate as bridging therapy after Prolia discontinuation [14].

Comparing Prolia to Other Covered Osteoporosis Agents

Blue Shield covers several osteoporosis agents that can serve as comparators during appeals:

| Agent | Formulary Tier | PA Required | Hip Fracture RRR | |-------|---------------|-------------|-----------------| | Alendronate 70 mg (generic) | Tier 1 | No | 47% (FIT trial) [5] | | Risedronate 35 mg (generic) | Tier 1 to 2 | No | 30% (HIP trial) [15] | | Zoledronic acid IV (generic) | Tier 3 (medical benefit) | Yes | 41% (HORIZON trial) [16] | | Prolia 60 mg (Prolia) | Tier 4 to 5 | Yes | 40% (FREEDOM trial) [1] | | Teriparatide (Forteo) | Tier 5 | Yes | Vertebral only (reduces by 65%) [17] | | Romosozumab (Evenity) | Tier 5 | Yes | 38% vs. Alendronate (ARCH trial) [18] |

When a patient has failed bisphosphonates or has a documented contraindication, Prolia is the next most evidence-supported option at comparable hip fracture risk reduction to zoledronic acid.

Key ICD-10 and HCPCS Codes for Billing

Correct coding is essential to avoid automatic denials. The codes below are the ones Blue Shield's claims system recognizes for Prolia authorization and billing.

Diagnosis Codes (ICD-10-CM)

• M81.0: Age-related osteoporosis without current pathological fracture
• M80.00XA/D/S: Age-related osteoporosis with current pathological fracture, unspecified site
• M81.8: Other osteoporosis without current pathological fracture (used for glucocorticoid-induced)
• Z79.52: Long-term (current) use of systemic steroids (required as secondary code for glucocorticoid-induced cases)
• C79.51: Secondary malignant neoplasm of bone (for oncology indications)

Procedure / Drug Codes

• HCPCS J0897: Injection, denosumab, 1 mg (bill 60 units for the 60 mg dose under Part B)
• NDC 55513-0730-01: Prolia 60 mg/mL single-use prefilled syringe (for pharmacy billing under Part D)

Submitting J0897 with 60 units, the appropriate ICD-10 primary diagnosis code, and a DXA Z-score reference in the claim notes reduces the rate of automatic denial in Blue Shield's claims adjudication system.